People · Operator
Named in public records as an officer, director or promoter · active 2012–2026 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Human Longevity, Inc. | — | Biotechnology | Series B | $59.0M | $398.9M | 2019 |
| OriGene Technologies, Inc. | — | Biotechnology | Series B | $38.6M | $676.8M | 2012 |
| CASI Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $30.0M | $12.3M | 2024 |
| Entremed Inc | — | Biotechnology | Series A | $10.0M | $361.5M | 2012 |
Wei-Wu He at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Wei-Wu He on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Hu | 2 | 3 |
| Quan Zhou | 1 | 5 |
| James Huang | 1 | 5 |
| Carolyn F. Sidor | 1 | 2 |
| David A. Cory | 1 | 2 |
| Anil Gupta | 1 | 2 |
| James A. Huang | 1 | 2 |
| Tom Bluth | 1 | 1 |
| Gene Dove | 1 | 1 |
| Wei Y. Gao | 1 | 1 |
| Alexander A. Zukiwski | 1 | 1 |
| Hai Y. Huang | 1 | 1 |
| Wei (Larry) Y. Zhang | 1 | 1 |
| Barbara A. Krebs-Pohl | 1 | 1 |
| Chunhua Y. Wang | 1 | 1 |
| Kun Y. Qian | 1 | 1 |
| Zhenbo Su | 1 | 1 |
| Thomas Folinsbee | 1 | 1 |
| Xuebo Y. Zeng | 1 | 1 |
| Alexander Y. Wu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.